about
Analysis of APAF-1 expression in human cutaneous melanoma progressionBisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidenceOvarian cancer standard of care: are there real alternatives?Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecanRole of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistanceRole of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patientsThe synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrenceReceptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patientsImpact of smoking on lung cancer treatment effectiveness: a review.New targets, new drugs for metastatic bone pain: a new philosophy.Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trialRaltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).Fatal thrombocytopenia and thrombocytopathia: an unusual onset of non-small cell lung cancer.Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancerGenetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy.The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients.New molecular targets in bone metastases.Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade.The antineoplastic treatment in the elderly.Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor.Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumabNatural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyBone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis.Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes.Classic Kaposi Sarcoma: to treat or not to treat?The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?The antineoplastic role of bisphosphonates: from basic research to clinical evidence.Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer.Tumour proliferation, angiogenesis, and ploidy status in human colon cancerPazopanib and pancreatic toxicity: a case report.Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging.Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.
P50
Q24315147-0C1CE8C7-7960-4A5F-A4D4-8691D5E58548Q26795493-0E31A4E2-1042-4700-ABCC-B34252A5F25CQ26862249-9AE4C120-E116-4291-A6D0-B190004A41C9Q27851573-D82CD4BA-62FA-4E61-AE68-4811708DEA8DQ28274019-4718F636-B7B0-46E3-B460-3B0EF2DA4BBEQ28277703-1D2B95B3-D063-4812-AF57-8B9A35F2F03CQ28294985-E98A0AB2-9E9D-45D9-8747-3F1D20A427BDQ28534969-2092AF4C-E0BF-4B7C-86F4-4EC5F9D3388EQ28740575-0982F4AF-5BC5-41C1-9688-4DF3F11B84FEQ30248968-201F33C2-46B7-4CE1-B2C8-C8A55EED4FD4Q30403253-FC95EC38-13E7-4C8F-9577-8127FE3957D3Q33242985-1CE4BC02-3305-4774-89DC-80130222B039Q33342930-1B971DFD-C700-4769-B535-7D9D82ACDB73Q33348832-AE1DAA07-B32B-4A50-A541-CA54E8F914B4Q33372501-21D474C3-7851-4645-BE75-4AA02D02312BQ33399656-4953A3B9-F7C6-4E8B-A26E-604205652A91Q33404411-37BB8D62-B2ED-4587-B3D5-22479476BC50Q33644262-C30218BE-D64C-4B97-AC6D-28689AAA2ACEQ33714950-FE958108-70B9-4E43-9127-253C052456D3Q33982331-4FE4C6C2-45B7-48C7-8F6D-4254EA4A1479Q34024907-100C8760-F2C6-4D21-9CA2-88770E7AF1BBQ34444495-A2579177-5CAB-4C83-B95D-F5A2E92B8AB7Q34574793-D932159B-4D6A-44B8-94A6-7AE1CD69BBBAQ34773438-99298BB1-B973-482F-AF72-0B5F6FF9622FQ34774141-249F91B3-37CB-44C0-98FB-73B2ABBDDDD1Q34825323-05AAFA8C-69A6-4D92-9879-4147EDDA3368Q35080143-39779D55-E4BB-464C-B8E1-D3F64364942AQ35083485-D4214107-1A33-4662-9090-712AA2AC7111Q35150452-AB892CAA-48AA-4FC9-A036-BD1B1CDF57C7Q35197256-1D49E519-B2E2-4960-8147-7FDC638B9B33Q35401782-BEC8E136-A8CA-4BD6-BBB9-E8CD2C6339CDQ35464515-AA485E6D-6574-4730-A03B-80DB1D6DFBE5Q35540836-5683C1B4-3974-4389-B48A-423EA6428B5EQ35587652-06B033BC-2483-4BEA-929D-66474E78D0D4Q35588363-6FCA1D30-F263-4728-A5CC-1BBB096D914AQ35588677-1E384EB8-9427-47E6-A7A3-AC54A80190D6Q35588810-ED717DFB-16A2-4D97-B85C-DDB2D527E47EQ35616735-D293EF4B-27C9-4DE9-B64A-352C1817D798Q35681555-5EF44D9B-3D13-4DA3-B490-1BC640D5666FQ35731141-8B876FA9-1A40-43EE-B768-253A01AB3AA0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Tonini
@ast
Giuseppe Tonini
@en
Giuseppe Tonini
@es
Giuseppe Tonini
@nl
Giuseppe Tonini
@sl
type
label
Giuseppe Tonini
@ast
Giuseppe Tonini
@en
Giuseppe Tonini
@es
Giuseppe Tonini
@nl
Giuseppe Tonini
@sl
prefLabel
Giuseppe Tonini
@ast
Giuseppe Tonini
@en
Giuseppe Tonini
@es
Giuseppe Tonini
@nl
Giuseppe Tonini
@sl
P106
P21
P31
P496
0000-0003-4442-8677